{"id":893,"date":"2020-08-26T09:32:18","date_gmt":"2020-08-26T09:32:18","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/pap-test-fluids-used-in-gene-based-screening-test-for-two-gyn-cancers\/"},"modified":"2021-01-08T11:08:47","modified_gmt":"2021-01-08T11:08:47","slug":"pap-test-fluids-used-in-gene-based-screening-test-for-two-gyn-cancers","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/pap-test-fluids-used-in-gene-based-screening-test-for-two-gyn-cancers\/","title":{"rendered":"Pap test fluids used in gene-based screening test for two Gyn cancers"},"content":{"rendered":"<p><span lang=\"EN-GB\">Cervical fluid samples gathered during routine Papanicolaou (Pap) tests are the basis of a new screening test for endometrial and ovarian cancers developed by researchers at the Johns Hopkins Kimmel Cancer Center.<\/span><br \/>\n<span lang=\"EN-GB\">PapSEEK detects mutations in DNA that have been identified for specific cancers sooner. Earlier detection of cancer could lead to earlier treatment and potentially better outcomes for patients.<\/span><br \/>\n<span lang=\"EN-GB\">The test uses cervical fluid samples to look for mutations in 18 genes, which are highly or commonly mutated in endometrial or ovarian cancers, and aneuploidy, the presence of abnormal numbers of chromosomes in cells. The researchers said their results showed the potential for mutation-based diagnostics to detect endometrial and ovarian cancers earlier.<\/span><br \/>\n<span lang=\"EN-GB\">\u201cMore than 86,000 U.S. cases of endometrial and ovarian cancer were diagnosed in 2017. Treatment often involves surgery and, in some cases, chemotherapy or radiation,\u201d said Amanda Nickles Fader, M.D., director of the Johns Hopkins Kelly Gynecological Oncology Service, Department of Gynecology and Obstetrics, and a corresponding author on this study.<\/span><br \/>\n<span lang=\"EN-GB\">\u201cAdditionally for young women who are diagnosed, loss of fertility is common. If we could detect the cancer earlier using a test like PapSEEK, the potential to achieve more cures and preserve fertility in select women could be realized.\u201d<\/span><br \/>\n<span lang=\"EN-GB\">Most cancers are curable if they are detected early, and the researchers are exploring ways to use cancer gene discoveries to develop cancer screening tests to improve cancer survival. They announced the development of CancerSEEK, a single blood test that screens for eight cancer types, and UroSEEK, a test that uses urine to detect for bladder and upper tract urothelial cancer.<\/span><br \/>\n<span lang=\"EN-GB\">PapSEEK targets the most common and most lethal gynaecological cancers, endometrial and ovarian cancer. There is currently no screening test for endometrial cancer and, due to the obesity epidemic, it is on the rise, particularly in younger women.<\/span><br \/>\n<span lang=\"EN-GB\">\u201cGynaecological cancers are responsible for approximately 25,000 deaths per year and are the third leading cause of cancer-related mortality,\u201d said Nickolas Papadopoulos, Ph.D., a senior author and an investigator at the Ludwig Center at Johns Hopkins. \u201cMost of the deaths are caused by tumours that metastasize prior to the onset of symptoms. With PapSEEK, we are aiming to detect these cancers early when they are most curable.\u201d<\/span><br \/>\n<span lang=\"EN-GB\">Since fluid from the Pap test occasionally contains cells from the endometrium or ovaries, researchers found they could detect cancer cells from these organs that are present in the fluid.<\/span><br \/>\n<span lang=\"EN-GB\">John Hopkins Kimmel Cancer Center<link https:\/\/www.hopkinsmedicine.org\/news\/media\/releases\/pap_test_fluids_used_in_gene_based_screening_test_for_two_gyn_cancers _blank external-link-new-window \"Opens external link in new window\">www.hopkinsmedicine.org\/news\/media\/releases\/pap_test_fluids_used_in_gene_based_screening_test_for_two_gyn_cancers<\/link><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cervical fluid samples gathered during routine Papanicolaou (Pap) tests are the basis of a new screening test for endometrial and ovarian cancers developed by researchers at the Johns Hopkins Kimmel Cancer Center. PapSEEK detects mutations in DNA that have been identified for specific cancers sooner. Earlier detection of cancer could lead to earlier treatment and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-893","post","type-post","status-publish","format-standard","hentry","category-e-news"],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/893"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=893"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/893\/revisions"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}